INNOPHARMA Drug Discovery
Contact information
- Drug discovery
- Screening
The INNOPHARMA platform is a high-throughput platform and European reference in early drug discovery. Recognized as one of the high-capacity centers of the European Research Infrastructure Consortium ERIC EU-OPENSCREEN.
INNOPHARMA offers a wide range of capabilities covering all stages of the early drug discovery process: from target identification to preliminary safety and toxicity assessment.
We have extensive experience, accumulated by the BioFarma group through research programs and collaborations with the pharmaceutical industry. We have evaluated hundreds of thousands of compounds and dozens of biological targets, as well as developed, automated, and implemented hundreds of fully integrated assays within early drug discovery cascades.
This work has enabled, to date, seventeen New Chemical Entities (NCEs) to advance to clinical trials thanks to successful public-private collaborations.
Innopharma is interested in collaborating with academic groups, biotech and pharmaceutical companies that need an expert and capable partner to effectively carry out hit finding, hit to lead, and lead optimization tasks. Our chemical library, with over 130,000 highly annotated compounds, is an excellent starting point for the discovery of new hits. Additionally, we perform target engagement assays, phenotypic assays, target deconvolution strategies, and the generation of biological reagents.
Innopharma participates in collaborative projects at both the Spanish and international levels, and actively seeks new opportunities to contribute to proposals where the platform adds value to the project.
Biotech Sanitaria
| Product / Service | Type | Aplication | Development phase |
|---|---|---|---|
| On-demand Services | Screening/Drug Discovery | R&D | |
| ADME Assays | Screening/Drug Discovery | R&D | |
| Preliminary ADME-Tox and Safety Assays | Screening/Drug Discovery | R&D | |
| Molecular Biology-Based Assays | Screening/Drug Discovery | R&D | |
| Biophysical Target Engagement Assays | Screening/Drug Discovery | R&D | |
| Functional assays | Screening/Drug Discovery | Ion Channels | R&D |
| Functional assays | Screening/Drug Discovery | Enzymatic Assays | R&D |
| Functional assays | Screening/Drug Discovery | Second Messenger Assays | R&D |
| Radioligand Binding Assays | Screening/Drug Discovery | Nuclear Receptors | R&D |
| Phenotypic Assays | Screening/Drug Discovery | Disease-Relevant Models | R&D |
| Phenotypic Assays | Screening/Drug Discovery | General Phenotyping | R&D |
| Radioligand Binding Assays | Screening/Drug Discovery | G Protein-Coupled Receptors (GPCRs) | R&D |
| Radioligand Binding Assays | Screening/Drug Discovery | Transporters | R&D |